Introduction
Molecular studies are uncovering the complexity of cellular responses to single and repeated ionizing radiation (IR) exposures. These responses in autocrine growth-regulated neoplastic cells involve the activation of the existing signal transduction network and include plasma membrane receptor Tyr kinases (RTKs), nonRTKs and their downstream effectors. Among these, cytoplasmic protein kinases transmit or generate stimulatory and inhibitory signals that converge, through altered cell cycle regulation and transcription modulation, to overall cellular responses. Such responses are cytoprotective or cytotoxic, promoting cell survival or cell death by apoptotic and nonapoptotic mechanisms, respectively. While ERBB RTKs do not primarily signal towards stress response pathways, such as JUN-NH 2 -terminal kinase (JNK) and P38, signal shunting between the mitogen-activated protein kinase (MAPK) and JNK cascades can occur at multiple levels.
Considering the relative timing of cellular responses after IR exposure, the activation of RTKs and nonRTKs (e.g., SRC) occurs within minutes and counts among the earliest events after irradiation next to the recognition of and signaling by DNA damage (see section on DNA repair). ERBB and other RTKs, such as insulin-like growth factor receptor (IGF-1R), signal primarily along cytoprotective pathways. Some ERBB receptors, for example, ERBB1, mediate pro-proliferative signals predominantly through MAPK, but also through phosphatidyl-inositol-3-kinase (PI3 K). In contrast, ERBB RTK signals towards PI3 K and AKT converge to survival-promoting antiapoptotic signals. Both of these IR-induced responses contribute to tumor cell radioresistance. Since IR induces the activation of all ERBB and other RTKs, the expression of which varies widely for different tumor cells, establishing the relative contribution of ERBB receptors to cytoprotective responses is challenging, as discussed in this review. A third mechanism contributing to ERBB RTKmediated radioresistance has been identified as transcription factor activation and enhanced cellular DNA repair capacity.
The IR-induced ERBB1/MAPK activation mediates cell proliferation after single and repeated IR exposures (Kavanagh et al., 1995; Contessa et al., 1999) and represents the likely molecular mechanism underlying accelerated repopulation that has been demonstrated in experimental systems (Denekamp, 1973; Durand, 1993) and is inferred from clinical radiotherapy outcome analyses (Withers et al., 1988; Bentzen and Thames, 1991; Fowler, 1991) . The recently demonstrated strong inverse relation between radiotherapeutic tumor control of head and neck squamous cell carcinomas and ERBB1 (or epidermal growth factor receptor (EGFR)) expression levels in tumors supports the contribution of EGFR to radioresistance (Ang et al., 2002) .
This review describes the molecular mechanisms of cytoprotective cellular responses to IR that are mediated by RTKs and non-RTKs and contribute to the radioresistance of tumor cells. The unique features of IR-and growth factor (GF)-mediated activation of ERBB RTKs are evaluated in the context of ERBB receptor expression profiles and their relative roles in contributing to the overall cytoprotective responses of tumor cells. Finally, the mechanisms of different modes of ERBB RTK inhibition are examined for their potential in tumor radiosensitization.
RTKs and radiation responses of neoplastic cells
The ERBB RTK network ERBB and other RTKs are critical components in the autocrine growth regulation of carcinoma and malignant glioma cells and are typically overexpressed in these cells (Earp et al., 1995; Carpenter, 2000) . The ERBB RTK network is comprised of four different receptors, all transmembrane proteins in the 170-190 kDa size range, with Cys-rich GF-binding domains in the extracellular (NH 2 -terminal) portion of the molecule and a hydrophobic membrane-anchoring segment. The intracellular domain carries the Tyr kinase catalytic domain and a number of Tyr residues, phosphorylation of which represents a critical step in the formation of signaling complexes (Rojas et al., 1996; Emlet et al., 1997; Gotoh et al., 1997; Tenev et al., 1997; Lenferink et al., 1998; Waterman et al., 1998; Biscardi et al., 1999; Levkowitz et al., 1999) . In addition to the expression or overexpression of wild-type ERBB receptors, many tumor cells express mutant receptors that exhibit truncations in their extracellular GF-binding domain, such as EGFRvIII, a receptor that is constitutively active and does not require activation by GFs .
The receptors are physiologically activated by GF ligands with specificities for different ERBB receptors, for example, EGF for ERBB1 and heregulin (HRG) for ERBB4 (Levitzki et al., 1991; Levitzki, 1997) . The role of ERBB2, a constitutively active receptor with no known ligand, is thought to enhance some of the oncogenic effects of ERBB1 (Earp et al., 1995; Carpenter, 2000; Shtiegman and Yarden, 2003) . However, we have shown that the function of ERBB2 in cellular responses to IR may be different and requires further study. The role of the kinase-inactive ERBB3 receptor, which shares GF-binding specificities with ERBB4, in cellular responses to IR remains poorly defined (Earp et al., 1995; Carpenter, 2000) .
Upon GF binding, for example, EGF to ERBB1, activation occurs through homodimerization and Tyr transphosphorylation. Phospho-Tyr residues of the cytoplasmic domain represent important docking sites for proteins that are involved in the formation of protein-signaling complexes. In addition to ERBB1 homodimerization, secondary activation events include the formation of heterodimers, for example, with ERBB2 or ERBB3 (Earp et al., 1995; Gamett et al., 1997; Shtiegman and Yarden, 2003) (Figure 1 ). Most recent results have shown that transactivation of RTKs is not limited to members of the ERBB family, but may extend to other RTKs, such as IGF-1R (Baserga, 1995; Turner et al., 1997; Chakravarti et al., 2002) . In addition to direct receptor interactions, non-RTKs, for example, SRC, facilitate receptor transactivation including signaling to cytoplasmic protein kinases.
The hierarchic activation of ERBB RTKs by GFs is contrasted by the effects of IR, which simultaneously activates all ERBB receptors expressed by a given tumor cell (Figure 1 ). Since the ERBB RTK expression profiles of different tumor cells vary substantially, the IRinduced responses by ERBB receptors are defined more by the ERBB RTK complement of cells than the GF specificity of the receptors. Importantly, despite simultaneous activation of RTKs by IR, their signaling specificities towards certain cytoplasmic protein kinase cascades remain preserved (Bowers et al., 2001; Contessa et al., 2002 ) (see Figure 2 ).
IR-induced activation of RTKs
IR in the 1-5 Gy dose range activates ERBB RTKs, within minutes as quantified by increases in receptor Tyr phosphorylation using phospho-Tyr-specific antibodies (Schmidt-Ullrich et al., 1997) . This two to fivefold increase in Tyr phosphorylation of ERBB1 can be contrasted to the 45-fold activation by EGF or TGF-a Dent et al., 1999; Reardon et al., 1999) . Transactivation of other ERBB receptors, such as Figure 1 ERBB RTK activation by ionizing radiation and growth factors; hierarchic vs. simultaneous activation. EGF and heregulin (HRG) bind to ERBB1 and -4 respectively, and activate the ERBB RTK network through hierarchic reactions. The growth factors primarily activate their respective receptors through homodimerization and transphosphorylation. Other ERBB receptors, for example, ERBB2 and -3, are activated secondarily upon heterodimerization (left panel). In contrast, IR induces the simultaneous activation of all ERBB receptors expressed by a given tumor cell; transactivation as a result of heterodimerization does occur but plays a minor role in receptor activation ERBB2, upon EGF stimulation of ERBB1, is typically o5-fold. Importantly, IR activates all ERBB receptors expressed by a given tumor cell to the same extent and with similar kinetics, demonstrating peak Tyr phosphorylation within 5-10 min (Bowers et al., 2001) . This simultaneous activation is the likely reason for the finding that IR signals downstream of the receptors are of similar intensity as those induced by GFs (Figures 2  and 3) . Importantly, the activation of the constitutively active EGFRvIII by IR is at least threefold greater than that of wild-type ERBB1, including its downstream signals towards the MAPK and AKT pathways (Chu et al., 1997; Wikstrand et al., 1997; Lammering et al., 2003) .
Besides the magnitude of activation, there are other potentially important differences in GF and IR effects on RTKs. ERBB1 demonstrates a biphasic activation response to IR, comprised of a 11 phase, between 1 and 10 min, and a more protracted 21 phase that extends beyond 60 min, depends on the initial activation, and appears to be mediated by the release of intrinsic TGF-a . These findings open the interesting possibility that different mechanisms are responsible for the 11 and 21 phases of activation with likely differences in ERBB1 Tyr phosphorylation patterns and receptor functions. The initial simultaneous activation of ERBB RTKs, occurring with similar kinetics for all RTKs, including IGF-1R, is most likely due to a common mechanism. One such mechanism could be the inhibition of protein Tyr phosphatases (PTPs) which have been implied in regulating steady-state Tyr phosphorylation of receptors. The inhibition of PTPs can occur when their catalytic site Cys residues react with reactive nitrogen species (RNS; Leach et al., 2001 Leach et al., , 2002 Mikkelsen and Ward, 2003) . In support of this concept, a number of PTPs have been identified in the plasma membrane and the endosomal membranes that interact with ERBB1 (Keilhack et al., 1998; Craggs and Kellie, 2001; Tonks and Neel, 2001; Tiganis, 2002) ; however, their chemical modification after irradiation of cells and their inhibition by RNS requires further investigation.
IR-induced activation of cytoplasmic protein kinases
While IR induces lower levels of ERBB1 Tyr phosphorylation than EGF, the functional consequences for some downstream pathways appear indistinguishable (Figure 2 ). The initial activation of ERBB receptors is reversible and usually falls to baseline activity levels within 10 min (Schmidt-Ullrich et al., 1996 , 1997 , 2000 Bowers et al., 2001) before the 2 o phase starts after 30 min. The immediate RTK activation by IR is closely followed by the stimulation of major signaling pathways with selective functional linkage to different members of the ERBB receptors (Figures 2 and 3 ). The stimulation of MAPK peaks between 5 and 15 min of IR exposure and is primarily linked to the activation of ERBB1 with additional contributions by RAS and RAF (Bernhard et al., 1998; McKenna et al., 2003) . All these components contribute to the pro-proliferative response As an important component of the IR-induced cytoprotective response, the proliferation response (in A431 cells) is expressed as a release from EGF-induced growth inhibition (panel, bottom right) (Kavanagh et al., 1995) through P90S6K/P70S6 K and the activation of certain transcription factors that are stimulated 30-60 min after irradiation Reardon et al., 1999; Amorino et al., 2002) .
Considering the interactions among ERBB receptors and their simultaneous activation, it is currently unclear to what extent IR-induced ERBB1 activation directly affects PI3 K and AKT, as suggested in other reports (Fry et al., 1998; Harari and Huang, 2001 ). Alternatively, and more likely, these pathways are activated directly by ERBB2 and ERBB3, as is suggested by studies, using selective receptor inhibition and/or overexpression in different carcinoma cells (Contessa et al., 2002, unpublished; Figures 2 and 4) . Based on these studies, ERBB2 generates unique antiapoptotic signals through AKT. ERBB3, which is partially dependent on other Tyr kinases, also contributes to IR-induced survival signaling through its recruitment and activation of PI3 K as a consequence of binding of the P85 subunit. In addition, ERBB2 and ERBB3 generate signals to other cytoplasmic kinases, including MAPK and P90S6 K. ERBB1, ERBB2 and ERBB3 initiate convergent signaling to P70S6 K that in turn stimulates translation as a component of the pro-proliferative response (Contessa et al., 2002) .
IGF-1R, another RTK frequently overexpressed in carcinoma cells, is activated by IR with kinetics similar to those of ERBB1 (Waterman et al., unpublished) . In COS-7 cells, IGF-1R synergizes with ERBB1 in stimulating downstream signaling pathways through transactivation -as shown by the IGF-1-mediated, increased Tyr phosphorylation of the P85 unit of IGF-1R, EGFR, SHC and MAPK1/2 (Roudabush et al., 2000) . The AG1478 inhibitor of ERBB1 attenuates Tyr phosphorylation of ERBB1, SHC and MAPK1/2, but has no effect on P85 (of IGF-1R), IRS-1 and AKT, thus preserving the receptors' antiapoptotic effects through PI3 K and AKT stimulation and the phosphorylation/ inactivation of BAD (Peruzzi et al., 1999; Swantek and Baserga, 1999) . These data emphasize the potential importance of IGF-1R on cellular IR responses. In addition, IGF-1R through its functional links to ATM and DNA-PK expression may have important effects on the cells' DNA repair capacity and radiosensitivity (Peretz et al., 2001) .
These IR effects are contrasted to GF-induced MAPK activation using overexpression of DN EGFR-CD533 and ERBB2-CD572 in MDA-MB-231 (expressing ERBB1 and -2) and T47D (expressing ERBB2, -3, -4) mammary carcinoma cells (MCCs) after exposure of cells to EGF and HRG, respectively. According to these studies, EGF-induced MAPK activation depends equally upon ERBB1 and ERBB2 function in MDA-MB-231 cells. A similar synergism exists between ERBB4 and ERBB2 in T47D cells after exposure to HRG. However, prolonged downregulation of ERBB1 in T47D cells causes almost complete inhibition of ERBB1 and ERBB2 results in compensatory increases in ERBB3 Tyr phosphorylation, a response that is SRC and IGF-1R dependent and that promotes a significant antiapoptotic response (Contessa et al., unpublished; Figure 4 ).
Inhibitors of ERBB RTKs
Owing to the diverse functions of ERBB receptors and the expression of usually multiple species by a given cell, ERBB-specific inhibitors have played an important role in advancing our understanding of receptor functions in human tumor cells. The different approaches to receptor inhibition were initially developed for ERBB1, the most extensively studied ERBB receptor, and include the following: (1) steric hindrance of GF binding by monoclonal antibody (mAb) (e.g., C225; Mendelsohn and Baselga, 2000) ; (2) quinazoline kinase inhibitors that block the ATP-binding site of the kinase domain and prevent autophosphorylation and transactivation (Levitzki et al., 1991; Levitzki, 1997; Fry et al., 1998; Allen et al., 2002; Solomon et al., 2003) ; (3) studies using point mutations that eliminated functionally important Tyr residues in the COOH-terminal domain (Rojas et al., 1996; Emlet et al., 1997; Gotoh et al., 1997; Tenev et al., 1997; Lenferink et al., 1998; Waterman et al., 1998; Biscardi et al., 1999; Levkowitz et al., 1999) culminated in the generation of a truncated receptor that lacked the 533 COOH-terminal amino acids, termed EGFR-CD533, and proved to act as dominant-negative (DN) ERBB1 mutants (Kashles et al., 1991) . Similar reagents are now available for ERBB2 in the form of the anti-ERBB2 mAb (Park et al., 2000) , the tyrphostin AG825 (Levitzki et al., 1991; Levitzki, 1997) 
Blockade of GF binding
The anti-ERBB1 mAb C225 is functionally characterized and inhibits ERBB1 Tyr kinase activation after incubation of cells for 41 h and most likely acts through interference with autocrine TGF-a stimulation of the receptor (Bonner et al., 2000; Mendelsohn and Baselga, 2000) . Based on published experimental data, the mechanisms of action of mAb C225 appear to differ from those of other inhibitors (Huang et al., 1999; Bonner et al., 2000) . The effective inhibition of ERBB1 Tyr phosphorylation fails to translate into inhibition of MAPK, a major downstream effector of ERBB1. The effects of IR on inactivated ERBB1 are unclear as well, since IR does not induce any receptor activation in the absence of an inhibitor (Bonner et al., 2000) . Despite the lack of MAPK inhibition, ERBB1 blockade by C225 retards cell proliferation or causes complete arrest in the G1 phase of the cell cycle (Chou et al., 1999) . In a number of different carcinoma cell lines, CDK2 is inhibited most likely as a result of elevated levels of P27
KIP1
, but not P21 CIP1 expression, which remains unchanged (Chou et al., 1999) . Effects on the cells' repair capacity in association with cell cycle checkpoint arrest are suggested by the relative redistribution of DNA-PK into the cytoplasm (Huang et al., 1999) . Another important effect of C225 that can be expected to contribute to radiosensitization is its promotion of apoptosis through the expression modulation of the apoptosis-regulating proteins, BCL-2 and BAX (Huang et al., 1999; Bonner et al., 2000) . Decreases in BCL-2 appear to be associated with increased BCL-2 phosphorylation, one form of BCL-2 inactivation. According to another report, the decrease in BCL-2 levels may be further enhanced by upregulation of the proapoptotic protein BAX (Bonner et al., 2000) . A more detailed understanding of the mechanisms of ERBB1 inhibition on the expression of apoptosis-regulating proteins requires studies on the activity of RTKs other than ERBB1 in different tumor cells (see below). Reflective of the pleiotropic effects of ERBB1, C225 has been shown to inhibit angiogenic and metastatic potential of tumor cells in vivo (Mendelsohn and Baselga, 2000) .
Inhibitors of the Tyr kinase domain
Since the kinase domain of ERBB1 is essential for ERBB1 activation through auto-or transphosphorylation, kinase inhibitors have been developed as a means of ERBB1 inhibition. These inhibitors are quinazoline derivatives that bind to the catalytic domain of the ATPbinding pocket. The earlier generation tyrphostins bind reversibly and have a spectrum of specificities for different ERBB RTKs (Levitzki, 1997) . Of these, the tyrphostin, AG1478, has been extensively characterized Bowers et al., 2001; Amorino et al., 2002; Contessa et al., 2002) . It inhibits ERBB1 selectively and quantitatively with profound effects on MAPK Reardon et al., 1999; Amorino et al., 2002) and downstream targets including ERBB1-dependent transcription factors (Amorino et al., 2002) . Tyrphostins with specificities for IFG-1R (AG1024) enhance IR-induced apoptosis in a spectrum of human carcinoma cells (Wen et al., 2001) ; more detailed studies suggest that this occurs through SRCdependent stimulation of ERBB3 (Contessa et al., unpublished) . Inhibition of ERBB2 Tyr phosphorylation by AG825 results in a compensatory increased stimulation of ERBB1 along the MAPK cascade after both IR and EGF stimulation of the ERBB1/-2 receptors in MDA-MB-231 MCCs (Bowers et al., 2001) . At concentrations with excellent ERBB1 specificity, the tyrphostins block GF-and IR-induced receptor activation, extending these effects to downstream targets, such as MAPK and the PI3K and AKT pathways, to varied extents Bowers et al., 2001; Nelson and Fry, 2001; Contessa et al., 2002; Solomon et al., 2003) . Some of these, in particular ZD1839 (Huang et al., 2002; Solomon et al., 2003) , have been utilized in vitro and in vivo to demonstrate therapeutic potential in combination with cytotoxic chemotherapeutic agents or IR (Huang et al., 2002; Solomon et al., 2003) . ZD1439 inhibits ERBB1 at 40.5 mm concentration, which also results in MAPK and AKT inhibition (Solomon et al., 2003) . At these concentrations, ZD1439 inhibits cell proliferation, induces cell cycle arrest in G1 and demonstrates radiosensitization in clonogenic survival and tumor growth delay assays (Huang et al., 2002; Solomon et al., 2003) . The relative hydrophobicities and relatively short half-lives of the first-generation tyrphostins necessitate repeated administration and generate some uncertainty about their mechanisms of action in vivo. Some of the disadvantages of the earlier generation tyrphostins are eliminated by the irreversible, covalently reacting quinazoline derivative, CI1033 (Fry et al., 1998; Nelson and Fry, 2001; Allen et al., 2002) . CI1033 inhibits ERBB1 and ERBB4 with minor effects on ERBB2. The inhibition of ERBB1 is likely responsible for the observed inhibition of MAPK activity, which lasts for B24 h; recovery thereafter is most likely due to re-expression of new ERBB1 receptors or leakiness of the RTK response in tumor cells due to compensatory responses (Bowers et al., 2001) . The simultaneous inhibition of AKT by CI1033 may be directly related to ERBB1 inhibition, but may also reflect reduced transactivation of other ERBB receptors, for example, ERBB2 or ERBB3. Based on its inhibition of MAPK and AKT, radiosensitization of tumor cells is most likely due to growth inhibition and stimulation of apoptosis (Rao et al., 2000 ; Figure 2 ).
Overexpression of DN RTKs
The third approach of inhibiting ERBB RTKs has been the overexpression of DN EGFR-CD533 that is not activated by GFs or IR. While various point mutations of COOH-terminal Tyr residues (Rojas et al., 1996; Emlet et Levkowitz et al., 1999) have been investigated for their effects on ERBB1 signaling, the only mutant that eliminates all pro-proliferative and transformating functions is EGFR-CD533 (Kashles et al., 1991) , which lacks the 533 COOH-terminal amino acids -including the Tyr kinase domain and all Tyr residues that represent docking sites for protein signaling complexes of the activated receptor (Rojas et al., 1996; Emlet et al., 1997; Gotoh et al., 1997; Tenev et al., 1997; Lenferink et al., 1998; Waterman et al., 1998; Biscardi et al., 1999; Levkowitz et al., 1999) . EGFR-CD533, when overexpressed in a variety of tumor cells, acts through the formation of nonfunctional heterodimeric receptor complexes (Kashles et al., 1991) . The expression of DN EGFR-CD533 is achieved in stably transfected human MCC and squamous carcinoma cells (SCCs) in which EGFR-CD533 is under the control of a tet-on expression system yielding 450-fold induction over background levels ; alternatively, the receptor is expressed at high levels through transduction of human tumor cells after infection with the adenoviral vector, Ad-EGFR-CD533 (Lammering et al., 2001a, b c; Contessa et al., 2002) . The continuous expression of DN EGFR-CD533 results in the complete blockade of all ERBB receptors, including ERBB1, -2, and -4; ERBB4 is inhibited even in cells that express undetectable levels of ERBB1 protein and appear to be growth regulated through the ERBB4/HRG receptor-ligand system, as applies with T47D MCCs (Bowers et al., 2001; Lammering et al., 2001b; Contessa et al., 2002) . GF-or IR-induced activation of ERBB3 is inhibited in cells that primarily express ERBB1 and ERBB2. Based on these data, overexpression of EGFR-CD533 exhibits a strong pan-ERBB inhibitory effect. However, the prolonged inhibition of all ERBB receptors, not surprisingly, facilitates compensatory responses by other members of the ERBB family and, likely, other RTKs. Overexpression of DN ERBB2-CD572 appears to be much less interfering relative to the effects of EGFR-CD533, supporting the relative hierarchy within the ERBB RTK response system (Contessa et al., unpublished) .
Compensatory responses
Prolonged highly effective inhibition of ERBB RTK function results in compensatory responses, as shown for different MCCs. Overexpression of EGFR-CD533 in T47D and MH3 cells (MDA-MB-231 cells stably overexpressing ERBB3; Contessa et al., unpublished) causes a 45-fold increase in basal ERBB3 activity. Importantly, the increased ERBB3 activity is associated with a marked antiapoptotic response that, in concert with SRC (Biscardi et al., 1999) , also protects cells from IR-induced apoptosis by 42-fold (Contessa et al., unpublished; Figure 4) . Another compensatory response relates to the inhibition of ERBB2 by AG825, which results in intensified and prolonged ERBB1 signaling along the MAPK pathway (Bowers et al., 2001 ).
Cellular IR response end points; components of the IR-induced cytoprotective response
Based on our current understanding, the overall cytoprotective response after irradiation is composed of pro-proliferative and antiapoptotic components that are at least in part initiated by RTKs and mediated by different, but interacting downstream protein kinase signaling pathways. In addition, transcriptional responses are induced that result in enhanced DNA repair ( Figure 5 ).
IR-induced proliferation
The mechanisms underlying IR-induced proliferation were originally defined for MCF-7 and MDA-MB-231 MCCs (Schmidt-Ullrich et al., 1994 , 1997 , 2000 and A431 SCCs (Kavanagh et al., 1995) . MCF-7 cells were irradiated using a clinically applied irradiation schedule with repeated 2 Gy daily IR exposures (Schmidt-Ullrich et al., 1994) . The 480% survival of cells after a single 2 Gy exposure permits the study of adaptive responses after repeated IR exposures. After a cumulative dose of 60 Gy in vitro (delivered in 2 Gy daily increments), surviving cells, MCF-IR-3 cells, were isolated and cloned for genetic and functional characterization (Schmidt-Ullrich et al., 1994) . Surviving cells exhibited an adaptive response with ninefold higher ERBB1 mRNA levels and increased ERBB1 protein expression; there was a concordant downregulation of mRNA levels of estrogen receptor and of the negative growth regulator, TGF-b (Schmidt-Ullrich et al., 1994) . In line with increased expression of ERBB1, MCF-IR-3 cells proliferated faster than the MCF-7 parent cells Figure 5 The inhibition of ERBB1 by incubation of cells with the Tyr kinase inhibitor AG1478 or overexpression of EGFR-CD533 completely blocks IR-and GF-induced ERBB1 Tyr phosphorylation. The overexpression of EGFR-CD533 completely blocks the IR-induced activation of downstream cytoplasmic protein kinases (AG1478 is partially active in this system). As a result, the IRinduced cytoprotective response is disrupted as manifested by elimination of the IR-induced proliferation, increased rates of apoptosis and reduced DNA repair (Schmidt-Ullrich et al., 1994) . The proliferation-stimulating effects of IR were more directly demonstrated in A431 SCCs expressing high levels of ERBB1. For these studies, A431 cells were growth arrested at low concentrations of EGF (1 ng/ml; Kavanagh et al., 1995) . The cells were then exposed to single IR doses between 0.25 and 5, and cell numbers were quantified after a 7-day proliferation period. There was an IR dosedependent stimulation of cell proliferation with the steepest dose-response relation between 0.5 and 2.0 Gy (Kavanagh et al., 1995) (Figure 3) . During consecutive studies, this assay was refined and specifically linked to ERBB1 function through the use of ERBB1-specific inhibitors in a repeated (three to five) IR exposure proliferation assay Reardon et al., 1999) . Results from these studies confirmed the importance of ERBB1 function in IR-induced proliferation in autocrine growth-regulated carcinoma cells and demonstrated that ERBB1 function was essential for cells to regain their proliferation capacity after irradiation (Schmidt-Ullrich et al., 1996 , 2000 . Under conditions of wild-type ERBB1 expression only, human MCC and SCC cells re-entered the proliferative state within 4-7 days after irradiation to an extent where proliferation rates exceeded those of unirradiated cells. In contrast, cells that were irradiated under conditions of EGFR inhibition, that is, after treatment with AG1478 or overexpression of DN EGFR-CD533, never recovered their proliferation potential resulting in threeto sevenfold lower cell numbers relative to control conditions Reardon et al., 1999) . This link of ERBB1 and downstream effects of MAPK/ PI3 K stimulation to IR-induced cell proliferation represents the likely mechanism of IR-induced accelerated repopulation (Akimoto et al., 1999; SchmidtUllrich et al., 1999; Ang et al., 2002) .
IR-induced apoptosis; modulation by ERBB RTKs
ERBB RTKs are directly or indirectly involved in modulating apoptosis after irradiation (Figure 4) . In MDA-MB-231 cells, the inhibition of ERBB2 with AG825 results in a twofold increase in apoptosis rates that are further enhanced by the additional inhibition of ERBB1 using AG1478. ERBB2 signals most likely through AKT since inhibition of ERBB2, through exposure of cells to AG825 or overexpression of DN ERBB2-CD572, quantitatively abolishes IR-induced activation of AKT (Contessa et al., 2002) . Whether the IR-induced apoptotic response depends exclusively upon ERBB2 requires additional investigation. However, ERBB1 affects IR-induced apoptosis as well since the expression of EGFR-CD533 (tet-on inducible expression) doubles the rates of apoptosis in MDA-MB-231 cells. These data are similar to reports of increased apoptosis with other ERBB1 inhibitors (Huang et al., 1999; Bowers et al., 2001) . Similar increases in apoptosis are seen after inhibition of MAPK through inhibition of MEK1/2 by PD98059 or of JNK and through the expression of the DN c-JUN, TAM67 . According to these studies, the basal apoptosis rates after irradiation are low, approximating 3%. The inhibition of ERBB RTKs or their downstream effectors raise these rates to B6%, although under some conditions higher apoptosis rates are observed. The inhibition of the antiapoptotic signaling pathways, involving IGF-1R, SRC and STAT3, could enhance IR-induced apoptosis (Huang et al., 1999; Bonner et al., 2000) .
ERBB-dependent repair of IR-induced DNA damage
The relative radioresistance conferred by ERBB1 and ERBB2 is defined by inhibition of these receptors and their effects on cell survival. More mechanistic studies are generating links between receptor function and DNA repair. Effects of ERBB1 inhibition on IRinduced transcriptional events establish different response patterns of transcription factor activation. Of more than 10 transcription factors studied, CREB, EGR, STAT-3 and ETS completely depended in their activation by IR upon the ERBB1/RAS/MAPK cascade (Amorino et al., 2002) . Since PCNA, induced by IR, is involved in cell cycle regulation and DNA repair and is transcriptionally regulated by CREB, we have studied the effects of PCNA expression on cell survival after irradiation. These studies were conducted in CHO with expression of DN CREB combined with the overexpression of PCNA. In clonogenic survival experiments, the radiosensitization by DN CREB was overridden by simultaneous overexpression of PCNA, demonstrating its role in the repair of IR-induced DNA damage . Other repair enzymes involved in base-excision repair, such as ERCC1 and XRCC1, are transcriptionally activated in prostate carcinoma cells, a response that depends upon ERBB1 or MAPK activity (Peretz et al., 2001; Yacoub et al., 2003) . The potential role of RTKs in DNA damage recognition and repair is also suggested by the recent findings on the relation between the expression of ATM/ DNA-PK and IGF-1R/ERBB1 (Baserga, 1995; Peretz et al., 2001) . The data presented in this section point to the growing evidence that IR-induced effects in different cellular compartments are linked through signal transduction responses.
ERBB1 inhibition and tumor cell radiosensitization
The prominent involvement of ERBB1 and ERBB2 in cell survival responses, including promotion of proliferation and inhibition of apoptosis, make these receptors attractive targets for therapeutic intervention. The inhibition of both ERBB1 and ERBB2 by immunochemical, pharmacological and genetic means results in radiosensitization of a variety of human tumor cells in vitro and in vivo.
In vitro studies
Most of the studies examining radiosensitization in vitro use single IR dose-response experiments and determine clonogenic survival (Fertil et al., 1984) . All the three categories of ERBB1 inhibitors have been tested for their radiosensitizing activity. While most studies correlate radiosensitization with the inhibition of ERBB1Tyr phosphorylation, the mechanisms of action may differ substantially for the different modes of ERBB1 inhibition (Huang et al., 1999; Reardon et al., 1999; Bonner et al., 2000; Rao et al., 2000; Lammering et al., 2001b, c; Contessa et al., 2002) . In addition, the varied extent of radiosensitization, additive (Bonner et al., 2000) or supra-additive (Rao et al., 2000; Lammering et al., 2001c) , may depend on the mechanism of ERBB1 inhibition and the choice of tumor cells, which differ significantly in their ERBB RTK expression profiles. Based on the findings described above, differences in the formation of ERBB homo-and heterodimeric complexes will generate different signals along proliferation-and apoptosis-regulating pathways and affect DNA repair (O'Rourke et al., 1998b; Pietras et al., 1999; Wilkinson and Staros, 2002) . Using standard clonogenic survival analyses, most reported IR doseenhancement ratios exceed values of 1.3 (Table 1 ). The radiosensitization is reflected in increases in the a and decreases in the b components of the linear-quadratic survival curves (Rao et al., 2000; Lammering et al., 2001b) .
The modification of survival parameters and the effects of receptor inhibition on SLDR split-dose experiments suggest that inhibition of DNA repair is an important cause of radiosensitization (Huang & Harari, 2000; Amorino et al., 2003) . The radiosensitization does not correlate with growth inhibition by different inhibitors when employed in the absence of IR Rao et al., 2000; Lammering et al., 2001c) , since MCCs and SCCs expressing DN EGFR-CD533 exhibit a minimal but statistically significant growth inhibition by B10%. In contrast, other MCCs, possibly due to different ERBB RTK expression profiles, demonstrate more profound effects after treatment with the kinase inhibitor CI1033 (Rao et al., 2000) . Importantly, the inhibition of proliferation in cells after irradiation is profound and is impressively demonstrated in cells expressing EGFR-CD533, an inhibitor of intrinsic TGF-a release and growth stimulation Dent et al., 1999; Reardon et al., 1999) . Repeated exposures of 2 Gy produce the same extent of radiosensitization after each IR exposure predicting highly significant effects with protracted irradiation schedules (Lammering et al., 2001b) .
Promotion of apoptosis as a result of ERBB1/ERBB2 inhibition has also been implicated as a factor contributing to radiosensitization (O'Rourke et al., 1998b; Huang et al., 1999; Bonner et al., 2000) . Increased rates of apoptosis have been reported in cells exposed to mAbs against ERBB1 and ERBB2 or the tyrphostins ZD1839 (Huang et al., 2002) and CI1033 (Rao et al., 2000) and upon overexpression of EGFR-CD533 Contessa et al., 2002) . In many incidences, the relatively low rates of apoptosis in carcinoma cells may not contribute to the clonogenic survival of cells. An exception may be tumor cells expressing high levels of ERBB3, for example, T47D MCCs, that exhibit rates 410% after a single IR exposure and simultaneous SRC inhibition by PP2 (Contessa et al., unpublished; Shah et al., 2003) . The mechanisms of ERBB inhibition on radiosensitization are complex and need to be investigated in more detail by defining the molecular events that convert ERBB RTK inhibition into a cellular survival or death response (see reviews Mendelsohn and Baselga, 2000; Schmidt-Ullrich et al., 2000; Harari and Huang, 2001 ).
In vivo studies
Preclinical studies using xenograft tumors of human tumor cells represent an important step of validating molecular targets, such as ERBB1 and other ERBB RTKs, for potential therapeutic intervention. Therefore, the inhibition of ERBB RTKs in vivo should be mechanistically linked to radiosensitization through clonogenic survival or tumor growth delay assays (Fry et al., 1998; Bonner et al., 2000; Solomon et al., 2003) or tumor control end points (Akimoto et al., 1999) . These studies, not always quantifying the extent of ERBB RTK inhibition in vivo, have uniformly demonstrated the sensitization of tumors by IR when combined with ERBB1 or ERBB2 inhibition. Tyrphostins, anti-EGFR mAb and DN EGFR-CD533 have generated significant tumor growth delays in combination with single and repeated IR exposures relative to appropriate controls. Reported enhancement ratios in vivo range from B1.3 to 44.0 (see refs. in Table 1 ). One study reported ex vivo clonogenic survival as a measure of in vivo radiosensitization (Lammering et al., 2001a) (Table 1) .
Different approaches of ERBB1 inhibition pose different challenges in either delivering systemically administered agents at effective concentrations to the tumor or in achieving satisfactory distributions within the tumor when administered through localized injection. The tyrphostins are relatively hydrophobic molecules with varied half-lives requiring repeated, possibly daily, administration. Some of the shortfalls should be corrected with newer generation compounds, such as CI1033 (Fry et al., 1998; Rao et al., 2000) . Greater systemic toxicities, however, will require careful evaluation. Anti-EGFR/-ERBB2 mAbs, for example, C225 and anti-ERBB2 mAbs, also require repeated intravenous systemic administrations with potential systemic toxicities. Most mAbs and tyrphostins carry a high degree of specificity for one ERBB receptor, such as ERBB1, with potential secondary effects on interacting receptors; these latter effects may be cell dependent because of different ERBB expression profiles. The currently available method of Ad-EGFR-CD533-mediated DN ERBB1 expression faces the challenges of intratumoral administration, although systemic administration via liposomal carriers should be possible (Kasid and Dritschilo, 2003) . However, the genetic approach bears the advantage of continuous expression of the therapeutic gene at high levels for several weeks after one or two administrations; the infusion of Ad-EGFR-CD533 into human carcinoma and glioma xenografts has generated transduction rates of 445% (Lammering et al., 2001a, b) . EGFR-CD533 also has pan-ERBB inhibitory activity with a pronounced growth inhibitory and radiosensitizing effect even in tumors expressing high levels of EGFRvIII, which is commonly expressed in xenograft and spontaneous tumors (Kuan et al., 1999; Lammering et al., unpublished) .
The exclusive in vivo expression of EGFRvIII (Kuan et al., 1999) , a ERBB1 mutant dominantly contributing to relative radioresistance of tumor cells, requires that ERBB1 inhibitors are active against EGFRvIII in vivo. In addition, studies in vitro and in vivo may generate different results since many of the ERBB RTK functions that affect interactions between tumor cells and normal tissue stromal cells cannot be studied in vitro (Mendelsohn and Baselga, 2000) .
Conclusions
ERBB RTKs critically contribute to the autocrine growth-regulated phenotype of carcinoma and malignant glioma cells. Since their activation in irradiated cells confers strong cytoprotective responses, receptor inhibition holds promise as a potential therapeutic intervention for radiosensitization. Thus, ERBB RTKs are identified as important therapeutic targets. However, the highly interactive nature of the ERBB RTK network, and its interaction with other RTKs, require a detailed mechanistic understanding to assure that sustained inhibition is achieved and cellular resistance is not induced by compensatory responses. Receptor tyrosine kinases and radiation responses RK Schmidt-Ullrich et al
